Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model

Conclusions This model projected that PHiD-CV would provide both incremental health benefits and cost-savings compared with PCV-13 at price parity. Using PHiD-CV could result in substantial budget savings to the NHS. These savings could be used to implement other life-saving interventions.
Source: BMJ Open - Category: Journals (General) Authors: Tags: Open access, Global health, Health economics, Health policy, Infectious diseases, Paediatrics Research Source Type: research